---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-042940"
form_type: "8-K"
ticker: "BBLG"
cik: "0001419554"
company_name: "Bone Biologics Corp"
filed_at: "2026-09-16T21:00:39+00:00"
generated_at: "2026-09-16T21:02:06.871548+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Bone Biologics gets Nasdaq bid-price delisting notice; plans reverse split vote

## Summary
- Nasdaq notice on Sept 10, 2026: BBLG common stock bid price below $1 for 30 consecutive sessions, violating Rule 5550(a)(2).
- 180-day compliance period runs to March 9, 2027; can cure with 10 straight business days at $1.00 or higher.
- If not cured, may qualify for additional 180-day period if other listing standards met; otherwise delisting proceedings start.
- Company intends to seek stockholder approval for a reverse stock split at upcoming annual meeting to regain compliance.
- Notice has no immediate effect on Nasdaq listing; management monitoring bid price and evaluating options.

## SEC filing metadata
- accession: 0001493152-26-042940
- form_type: 8-K
- ticker: BBLG
- cik: 0001419554
- company_name: Bone Biologics Corp
- filed_at: 2026-09-16T21:00:39+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419554/000149315226042940/0001493152-26-042940-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419554/000149315226042940/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-042940
- JSON: https://secwatch.observer/filing/0001493152-26-042940.json
- Plain text: https://secwatch.observer/filing/0001493152-26-042940.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.